Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Add To Watchlist

Recent & Breaking News (NYSEAM:TOVX)

Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis)

PR Newswire September 12, 2014

Synthetic Biologics to Host Phase II Trimesta(TM) for Multiple Sclerosis Conference Call

PR Newswire September 11, 2014

Synthetic Biologics to Webcast September 16, 2014 Irritable Bowel Syndrome (IBS) Investor Day

PR Newswire September 10, 2014

Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program

PR Newswire September 8, 2014

Synthetic Biologics Highlights New Data from C. difficile Program Presented at the 54th ICAAC

PR Newswire September 7, 2014

Synthetic Biologics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City

PR Newswire September 3, 2014

Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections

PR Newswire September 2, 2014

Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile

PR Newswire August 28, 2014

Synthetic Biologics Announces Presentation of Poster for SYN-004 C. difficile Program at IDWeek 2014(TM)

PR Newswire August 26, 2014

Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC

PR Newswire August 19, 2014

Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights

PR Newswire August 14, 2014

Synthetic Biologics to Host Irritable Bowel Syndrome (IBS) Investor Day

PR Newswire August 13, 2014

Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at 54th ICAAC

PR Newswire August 12, 2014

Synthetic Biologics to Report Second Quarter 2014 Financial Results

PR Newswire August 7, 2014

Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile

PR Newswire August 5, 2014

Biotechnology Sector in Focus

Accesswire July 31, 2014

Expanded Data on Disability and Cognitive Improvements in Phase II Study of Synthetic Biologics' Trimesta(TM) in Multiple Sclerosis to be Presented at 2014 Joint ACTRIMS-ECTRIMS Meeting

PR Newswire July 31, 2014

Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity

PR Newswire July 29, 2014

Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough (Pertussis) at Gordon Research Conference

PR Newswire July 21, 2014

Synthetic Biologics Forms Clinical Advisory Board to Support Novel C. difficile Preventative Program

PR Newswire June 30, 2014